Denise A. Yardley, MD
With the approval of 3 CDK4/6 inhibitors, the frontline treatment landscape of hormone receptor (HR)–positive, HER2-negative metastatic breast cancer has evolved with chemotherapy no longer being the go-to approach, said Denise A. Yardley, MD.
In March 2017, the FDA granted a full approval to palbociclib (Ibrance)
in combination with letrozole as a frontline treatment for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer, based on data from the confirmatory phase III PALOMA-2 trial (NCT01740427). Palbociclib is also indicated for use in combination with other aromatase inhibitors (AIs) in this setting.
In April 2019, the FDA expanded the indication for palbociclib
plus an AI to include men with HR-positive, HER2-negative advanced or metastatic breast cancer.
... to read the full story